Jesus Rodriguez Hernandez, MD
Pulmonary Disease · Weslaco, TXNPI 1780067710
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,702 of the $2,568 with a category attached, or 66.3%. Inspire Medical Systems, Inc. accounts for 66.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $2,073 and has fallen 88.6% since, to $237 in 2025. That places this record below the midpoint for pulmonary disease clinicians in TX, where the typical reported total is $1,976.
Across 14 payments — averaging $183.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- Melinta Therapeutics, LLC$248
- Medtronic$141
- Mylan Specialty L.p.$123
- Boehringer Ingelheim$120
- Harmony Biosciences LLC$94
- plus $134 from 4 others
What the payments were for
- Travel & lodging$86634%
- Food & beverage$1,70266%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 2 | $1,709 |
| Melinta Therapeutics, LLC | 2 | $248 |
| Medtronic | 1 | $141 |
| Mylan Specialty L.p. | 2 | $123 |
| Boehringer Ingelheim | 1 | $120 |
| Harmony Biosciences LLC | 1 | $94 |
| Fisher & Paykel Healthcare Inc | 2 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| AbbVie | 1 | $22 |
| Philips North America LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire Upper Airway Stimulation System$1,709
- ILLUMISITE$141
- Vabomere$124
- Kimyrsa$123
- OFEV$120
How this compares
$2,568 in reported general payments places this provider in the 50th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $27,467 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $15,022 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $4,111 |
| Ventolin HfaAlbuterol Sulfate | 14 | $778 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $762 |
| Azelastine Hcl | 18 | $331 |
| Fluticasone Propionate | 29 | $329 |
| Montelukast Sodium | 18 | $218 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Weslaco
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Zeenat SafdarHouston$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.